Drug Type Small molecule drug |
Synonyms Florastamin[18F], FC-303 |
Target |
Action inhibitors, enhancers |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 3 | China | 20 Oct 2023 | |
Localized Prostate Carcinoma | Phase 3 | China | 20 Oct 2023 | |
Oligometastatic Prostate Carcinoma | Phase 3 | China | 20 Oct 2023 | |
PSMA-Positive Prostatic Cancer | Phase 3 | China | 13 Sep 2023 | |
Metastatic Prostate Carcinoma | Phase 3 | United States | 08 May 2023 | |
Prostatic Cancer | Phase 3 | South Korea | 13 Aug 2021 |
Phase 3 | 138 | rdhrrgiutk(wnklgyrhyt) = weugzkiwij hurjgwrvip (wnjdaxxoxg ) View more | Positive | 10 Jul 2025 | |||
Phase 1 | 12 | (MRI with the best performing threshold of ≥ 4) | aescifzvpm(gymtzrlwvj) = rxsugjbdoq aefllcgqrz (wnjpjpzktp ) View more | Positive | 07 Dec 2024 | ||
(at 60 minutes) | aescifzvpm(gymtzrlwvj) = zmgxjsdnir aefllcgqrz (wnjpjpzktp ) View more |